The abstract is read at the publisher; the summary is JClub's.
Intravenous tirofiban plus aspirin did not significantly reduce early neurological deterioration or new stroke versus aspirin alone in 970 Chinese patients with BAD-related acute ischemic stroke.
- Why it matters: BAD-related stroke has high risk of early neurological deterioration and disability, but large trials testing intensified antiplatelet strategies to prevent deterioration and recurrence were lacking.
- What they did: In a multicenter, double-blind, placebo-controlled STRATEGY randomized clinical trial across 38 hospitals in China, patients with BAD-related stroke confirmed within 48 hours received tirofiban or placebo plus aspirin, with outcomes assessed through 90 days.
- The result: The primary endpoint occurred in 17.1% with tirofiban versus 19.6% with placebo (hazard ratio 0.88; 95% CI 0.65-1.19; P=.39), and moderate or severe bleeding was 0.2% versus 0% (P>.99).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.